Overview

The current portfolio is expected to face significant financial uncertainties driven by LoE (Loss of Exclusivity). The company wants to develop a strategy in Immunology to strengthen its innovative medicines portfolio for value creation. RxC was asked to develop a therapeutic area strategy to achieve long-term objectives.

Approach

RxC worked closely with the client team to:

• Identify diseases of interest based on future unmet needs and size.

• Identify mechanisms of interest within each disease.

• Prioritize pre-clinical/clinical opportunities in neuroscience and immunology.

• Develop a strategic roadmap highlighting near-term, mid-term, and long-term opportunities.

• Develop a preliminary plan for BD & M&A transactions.

Results

The client has shared key findings with executive management regarding strengthening the immunology in-line and pipeline portfolio. As a result, the company now has a clearer understanding of potential areas for growth and innovation.